Skip to main content

Table 2 Cohort characteristics of the training and validation cohorts

From: A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

Patient clinical characteristics Training Validation
n (%) 268 (65.4) 140 (34.6)
Benign 123 (44) 59 (41)
PCa 145 (52) 81 (57)
Gleason score
 6 60 (41) 36 (44)
 7 55 (38) 28 (35)
 8–10 30 (21) 17 (21)
Clinical T stage
 T1 101 (70) 48 (59)
 T2 25 (17) 16 (20)
 T3 11 (8) 11 (14)
 T4 8 (6) 6 (7)
% Biopsy cores positive for PCa
 Median 29% 33%
 Range 5–100% 5–100%
 Interquartile range 13%–55% 14%–63%
 N/A 8 6
Age at enrollment
 Median 66 66
 Range 42–85 37–85
 Interquartile range 59–71 59–72
PSA at presentation
 Median 6.9 7.04
 Range 0.01–248 0.04–377.00
 Interquartile range 4.55–10.36 4.79–11
Prostate volume
 Median 7 49
 Range 18.0–121.6 18.0–121.6
 Interquartile range 39.15–68.68 37–65.1
 N/A 114 58
Perineural invasion
 Yes 30 13
 No 97 55
 N/A 153 75
CAPRA risk
 CAPRA low 47 (32) 33 (41)
 CAPRA intermediate 56 (39) 26 (32)
 CAPRA high 42 (29) 22 (27)
D’Amico risk
 D’Amico low 41 (28) 28 (35)
 D’Amico intermediate 57 (39) 24 (30)
 D’Amico high 47 (32) 29 (36)